Phase I Safety and Immunogenicity of Live Attenuated Influenza H5 Candidate Vaccine Strain A/17/Turkey/Turkey/05/133 (H5N2) in Healthy Thai Volunteers
|Preventive Avian Flu||Biological: Avian Flu Vaccine Biological: Placebo||Phase 1|
|Official Title:||Phase I Safety and Immunogenicity of Live Attenuated Influenza H5 Candidate Vaccine Strain A/17/Turkey/Turkey/05/133 (H5N2) in Healthy Thai Volunteers|
|Study Start Date:||May 2012|
|Primary Completion Date:||August 2012 (Final data collection date for primary outcome measure)|
|Active Comparator: A/17/turkey/Turkey/05/133 (H5N2)||Biological: Avian Flu Vaccine|
|Placebo Comparator: Placebo||Biological: Placebo|
It is a phase I randomized placebo controlled trial (vaccine and placebo ratio of 2:1). A phase II study is planned to be conducted following review of results of this phase.
Phase I: It is a double blind randomized placebo controlled trial involving 24 participants age 18-49 years (16 will receive vaccines and 8 will receive placebo). All will be admitted in the isolation ward for 10-14 days after each immunization mainly for safety assessment. Two doses of live attenuated influenza H5 vaccine candidate strain A/17/turkey/Turkey/05/133 (H5N2) will be given by intranasal route 21 days apart. Each group of 4 participants will be immunized at a time at 30-60 mins interval. All participants will be followed 21 days after each immunization. Total follow up is 60 day.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01656356
|Faculty of Tropical Medicine|
|Bangkok, Thailand, 10400|